[{"address1": "100 Cambridgepark Drive", "address2": "Suite 101", "city": "Cambridge", "state": "MA", "zip": "02140", "country": "United States", "phone": "617 655 6580", "website": "https://www.vorbio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. The company offers the Vor Bio platform, a technology platform for the treatment of acute myeloid leukemia (AML) and other blood cancers. It develops tremtelectogene empogeditemcel (trem-cel), a genome-edited hematopoietic stem and progenitor allogeneic donor product candidate to treat acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and other blood cancers; trem-cel in combination with Mylotarg to treat patients in VBP101, which is in phase 1 / 2; and VCAR33, a CAR-T therapy designed to target CD33, which is under preclinical studies to treat AML post-transplant. The company also develops trem-cel + VCAR33 treatment system, CD33-directed CAR-T program, which is under pre-clinical studies for the treatment of AML; VADC45 for the treatment of hematologic malignancies, conditioning, and immune reset, which is under preclinical studies; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-edited HSC therapy and a CD33-CLL1 multi-specific CAR-T therapy, which is under preclinical studies for the treatment of AML. It has a license agreement with Columbia University and the National Institutes of Health for patents; and with Editas Medicine, Inc. for ex-vivo Cas9 gene-edited HSC therapies for the treatment and/or prevention of hematological malignancies. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.", "fullTimeEmployees": 154, "companyOfficers": [{"maxAge": 1, "name": "Dr. Robert  Ang M.B.A., M.D., MBBS", "age": 49, "title": "Strategic Advisor", "yearBorn": 1975, "fiscalYear": 2024, "totalPay": 994049, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Jean-Paul  Kress M.D.", "age": 59, "title": "Chairman & CEO", "yearBorn": 1965, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Siddhartha  Mukherjee DPHIL, M.D., Ph.D.", "age": 53, "title": "Scientific Founder & Chairman of Scientific Advisory Board", "yearBorn": 1971, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Sandesh  Mahatme L.L.M.", "age": 59, "title": "Chief Business Officer & CFO", "yearBorn": 1965, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Adi  Osovsky", "title": "General Counsel", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Tania  Philipp", "age": 52, "title": "Chief People Officer", "yearBorn": 1972, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Qing  Zuraw M.B.A., M.D., M.P.H.", "title": "Chief Development Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Dallan  Murray", "age": 54, "title": "Chief Commercial Officer", "yearBorn": 1970, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Navid Z. Khan", "title": "Chief Medical Affairs Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Jeremy  Sokolove M.D.", "title": "Chief Medical Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 10, "compensationRisk": 10, "shareHolderRightsRisk": 8, "overallRisk": 10, "governanceEpochDate": 1761955200, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 18.8, "open": 9.6, "dayLow": 9.0, "dayHigh": 10.21, "regularMarketPreviousClose": 18.8, "regularMarketOpen": 9.6, "regularMarketDayLow": 9.0, "regularMarketDayHigh": 10.21, "payoutRatio": 0.0, "beta": 2.02, "forwardPE": -8.338984, "volume": 9155829, "regularMarketVolume": 9155829, "averageVolume": 376303, "averageVolume10days": 369170, "averageDailyVolume10Day": 369170, "bid": 7.31, "ask": 9.96, "bidSize": 2, "askSize": 1, "marketCap": 67442448, "fiftyTwoWeekLow": 2.62, "fiftyTwoWeekHigh": 65.8, "allTimeHigh": 1272.4, "allTimeLow": 2.62, "fiftyDayAverage": 31.3233, "twoHundredDayAverage": 24.759125, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": -138236912, "profitMargins": 0.0, "floatShares": 4514606, "sharesOutstanding": 6853907, "sharesShort": 911582, "sharesShortPriorMonth": 1347089, "sharesShortPreviousMonthDate": 1759190400, "dateShortInterest": 1761868800, "sharesPercentSharesOut": 0.133, "heldPercentInsiders": 0.28776, "heldPercentInstitutions": 0.24966998, "shortRatio": 1.86, "shortPercentOfFloat": 0.31260002, "impliedSharesOutstanding": 6853907, "bookValue": -239.673, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1751241600, "netIncomeToCommon": -1664425984, "trailingEps": -273.6, "forwardEps": -1.18, "lastSplitFactor": "1:20", "lastSplitDate": 1758240000, "enterpriseToEbitda": 0.416, "52WeekChange": -0.019812286, "SandP52WeekChange": 0.14151978, "quoteType": "EQUITY", "currentPrice": 9.84, "targetHighPrice": 64.0, "targetLowPrice": 8.0, "targetMeanPrice": 45.5, "targetMedianPrice": 55.0, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 4, "totalCash": 200564992, "totalCashPerShare": 31.664, "ebitda": -332087008, "totalDebt": 0, "quickRatio": 3.413, "currentRatio": 3.487, "returnOnAssets": -1.21291, "freeCashflow": -149535632, "operatingCashflow": -113598000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "VOR", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "Vor Biopharma Inc.", "longName": "Vor Biopharma Inc.", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1612535400000, "postMarketChangePercent": 0.10162834, "postMarketPrice": 9.85, "postMarketChange": 0.010000229, "regularMarketChange": -8.96, "regularMarketDayRange": "9.0 - 10.21", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 376303, "fiftyTwoWeekLowChange": 7.2200003, "fiftyTwoWeekLowChangePercent": 2.7557254, "fiftyTwoWeekRange": "2.62 - 65.8", "fiftyTwoWeekHighChange": -55.960003, "fiftyTwoWeekHighChangePercent": -0.85045594, "fiftyTwoWeekChangePercent": -1.9812286, "earningsTimestampStart": 1762981200, "earningsTimestampEnd": 1762981200, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -273.6, "epsForward": -1.18, "epsCurrentYear": -54.02, "priceEpsCurrentYear": -0.18215476, "fiftyDayAverageChange": -21.4833, "marketState": "PREPRE", "regularMarketChangePercent": -47.6596, "regularMarketPrice": 9.84, "fiftyDayAverageChangePercent": -0.6858568, "twoHundredDayAverageChange": -14.919125, "twoHundredDayAverageChangePercent": -0.6025708, "priceToBook": -0.04105594, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2021-02-05", "averageAnalystRating": "2.0 - Buy", "cryptoTradeable": false, "market": "us_market", "esgPopulated": false, "corporateActions": [], "postMarketTime": 1762909126, "regularMarketTime": 1762894800, "exchange": "NMS", "messageBoardId": "finmb_572078292", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "displayName": "Vor Biopharma", "trailingPegRatio": null, "__fetch_time": "2025-11-12"}]